To be cost-effective, Biogen should slash Spinraza price, and Novartis cannot justify a $4M-$5M price tag for Zolgensma — ICER
As treatments for rare diseases and gene therapies make strides on the US market, the issue of pricing is once again center stage. Biogen should …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
